Ask The Board

  1. What Are The Current Trends For Where Compliance Reports In Small To Midsize Life Sciences Companies?
    10/4/2018

    See the answer from Jason Urban, Ph.D., the head of Celgene’s Business Operational Excellence function.

  2. How Can We Get Away From Blaming Human Error Or Training During The RCA (Root Cause Analysis) Process Of CAPA (Corrective And Preventative Action) And Instead Get To The True Root Of The Issue?
    10/4/2018

    See the answer from Andrew Skibo, head of global biologics operations & global engineering at MedImmune/AstraZeneca.

  3. How Do You Build A System At A Life Sciences Company That Is “Fit For Purpose”?
    10/4/2018

    See the answer from Charlene Banard, head of global quality and technical operations at Shire Pharmaceutical. She has more than 25 years of industry experience.

  4. Are Patientless Clinical Trials A Reality Or A Fantasy?
    9/3/2018

    See the answer from Tomasz Sablinski, MD, Ph.D., cofounder and CEO of Transparency Life Sciences.

  5. What Do You Look For In Board Members/Advisors?
    9/3/2018

    See the answer from Leslie Williams, president, CEO, and founder of ImmusanT. She has more than 20 years of industry experience.

  6. Where Should Biotech Companies Recruit Scientists For The Future, And How Should Universities Prepare Students To Be The Biotech Workforce For The Future?
    9/3/2018

    See the answer from Rachel King, CEO of GlycoMimetics, a publically traded biotechnology company. She has nearly 30 years of experience in various management roles in the biotech and pharmaceutical industries.

  7. When Do You Think BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In Clinical Research?
    8/2/2018

    See the answer from John Hubbard, Ph.D., a member of the board of Agile Therapeutics and former CEO of Bioclinica.

  8. What Are Pharma Companies Doing To Provide Greater Commitment To Ethical Practices And Transparencies Along With Corporate Social Responsibility?
    8/2/2018

    See the answer from Kenneth Moch, president and CEO of Cognition Therapeutics.

  9. What Are The Socioeconomic Impacts Of Life-Span-Extending Medicines And Treatments? What Developments Are Really Promising?
    8/2/2018

    See the answer from David Pyott, chairman of Bioniz Therapeutics, a small startup in Irvine, CA.

  10. How Will Pharma Sponsors Comply With PDUFA VI Requirements Related To Collecting/Submitting “Voice Of The Patient” Data As Part Of Their NDA?
    7/5/2018

    See the answer from Sandy Macrae, M.B., Ch.B., Ph.D., CEO of Sangamo Therapeutics. He has over 20 years of leadership experience in the pharmaceutical industry.